Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Cubana de Medicina
versión On-line ISSN 1561-302X
Resumen
RAMON CONCEPCION, Iván et al. Quality of life in patients suffering from bone metastasis due to prostate cancer treated with zoledronic acid. Rev cubana med [online]. 2021, vol.60, n.1 Epub 25-Feb-2021. ISSN 1561-302X.
Introduction:
Zoledronic Acid improves the quality of life of patients suffering from prostate cancer.
Objectives:
To assess the health-related quality of life using EORTC QLQ-BM22 questioner in patients suffering from prostate cancer, treated with zoledronic acid.
Method:
A prospective-descriptive study was carried out in 71 patients suffering from prostate cancer involving bones, with ages ranging between 18 and 80 years, and who were treated in the oncology service at Hermanos Ameijeiras Hospital. The ECOG was less than 3, life expectancy> 6 months, and follow-up of at least twelve months. Zoledronic acid was administered every 21-28 days. The visual analog scale and EORTC QLQ-BM22 module were applied.
Results:
The patients had median age of 71 years, Gleason ≥ 8: in 57.7% of the patients, PSA at diagnosis ≥ 20 ng / mL: 70.4%, ECOG 1: 67.6%, and stage IV as initial presentation: 50.7%. Bone metastases without visceral intake: 84.5%, in vertebrae 36.6%, <3 sites 66.2%, and blast bone metastases 60.6%. Skeletal events related to zoledronic acid before 7.9% (fracture), and after 5.6% (anti-allergic radiotherapy). At twelve months, according to the visual analog scale, a complete response was achieved, 71%, and a partial response, 29% (p <0.05). After the application of EORTC QLQ-BM22 module, a significant decrease was found in both the symptom and functional scales, regardless of other factors.
Conclusions:
Specific treatments for prostate cancer combined with zoledronic significantly improve pain and health-related quality of life in patients with bone metastases.
Palabras clave : quality of life; Zoledronic acid; bone metastases; prostate cancer.